AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01135914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
Study NCT01135914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
Study NCT01135914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
Study NCT02078102 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Meloxicam
Description: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
Study NCT02078102 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: Filgrastim will be subcutaneously injected in one or two sites at home.
Study NCT00642148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: Active tablet
Study NCT00642148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet and inhaler
Study NCT00642148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet and inhaler
Study NCT00642148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet and inhaler
Study NCT00642148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Active comparator inhaler
Study NCT00885638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg sitagliptin before ingestion of macronutrient
Study NCT00885638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo tablet is given before ingestion of macronutrients
Study NCT01031940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq device
Description: intubate with the Airtraq device
Study NCT00402714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal photopheresis
Description: Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
Study NCT00402714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentostatin
Description: pentostatin 8mg/m2 over 48 hours by continuous infusion
Study NCT00402714 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: 600cGy TBI in 3 200cGy TBI fractions
Study NCT01511328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV testing
Description: Testing for Human Papilloma Virus
Study NCT01591421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
Study NCT01591421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
Study NCT02032693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Everycell™
Study NCT02032693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01964599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PF-RS
Description: n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
Study NCT01964599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PF-RO1
Description: n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
Study NCT01964599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PF-RO2
Description: n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
Study NCT01964599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control
Study NCT01583166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 10ml 0.5% bupivacaine
Study NCT01583166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10ml 0.9% sodium chloride
Study NCT01583166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 1:200,000 epinephrine
Study NCT01052935 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Group B streptococcus (GBS) vaccine
Description: No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study.
Study NCT00794807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
Study NCT04205669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl Benzoate 25% Topical Application Lotion
Description: Applied to skin for the treatment of scabies
Study NCT03386786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Partner
Description: Health Partner is a combination of a mobile application and a web-based portal.
Study NCT03386786 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
Study NCT02721121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circumferential pulmonary vein isolation
Study NCT02891460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40 mg MMC in 40 mL TC-3.
Description: A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
Study NCT02891460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 80 mg MMC in 40 mL TC-3.
Description: A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
Study NCT02721121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Linear ablation in addiction to circumferential pulmonary vein isolation
Study NCT04094649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Vagus Nerve Stimulation (DECIMA)
Description: This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
Study NCT04094649 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound Vagus Nerve Stimulation (DECIMA)
Description: This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
Study NCT01125969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
Study NCT01125969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
Study NCT01125969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
Study NCT01125969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Description: Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
Study NCT04195789 — intervention group
Intervention type: OTHER
Intervention: Lung sonography
Description: Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.~Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist.
Study NCT00777049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Hard gelatine capsule - 5mg and 20mg
Study NCT00428220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: sunitinib
Study NCT01563289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 3 times a day
Study NCT01563289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times a day
Study NCT00167180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Donor Lymphocyte Infusion
Description: donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
Study NCT03610867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furaprevir capsule (SAD)
Description: There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.
Study NCT03610867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furaprevir capsule (MAD)
Description: There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
Study NCT00167180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Chemotherapy
Description: Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
Study NCT01289223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine IV
Study NCT01289223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Physicians Choice
Description: Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
Study NCT02855723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery: GS strategy
Description: sentinel node biopsy
Study NCT02855723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surgery: Classic strategy
Description: systematic lymphadenectomy
Study NCT00871546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
Study NCT02716103 — intervention group
Intervention type: OTHER
Intervention: blood collection
Study NCT02716103 — intervention group
Intervention type: OTHER
Intervention: bone marrow collection
Study NCT03447756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: Capsules of either 2mg, 10mg, or 50mg
Study NCT03447756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo to match
Study NCT03442907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24 hour blood pressure measurement, fluids, vasopressors
Description: Targeting individual blood blood pressure values during surgical procedures
Study NCT03442907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Treatment according to Standard of care at the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf
Study NCT02252198 — intervention group
Intervention type: OTHER
Intervention: Epistem Genedrive® and MolBio Truenat™
Description: S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2\*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
Study NCT00616655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eszopiclone
Description: SEP-225441 (eszopiclone) total daily dose of 1.5 mg
Study NCT00616655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eszopiclone
Description: SEP-225441 (eszopiclone) total daily dose of 0.9 mg
Study NCT00616655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo total daily dose 0.9 mg
Study NCT00867425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Lifestyle Management
Description: The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity).
Study NCT01079091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADVOS (Hepa Wash)
Description: Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)
Study NCT01079091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard of care treatment
Study NCT01863225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
Study NCT00943969 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: gastric bypass
Description: gastric bypass combines restrictive and malabsorptive procedures
Study NCT01049516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy - Massed
Description: 10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
Study NCT03336528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degludec
Description: Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner blood glucose (BG) between 100 mg/dL and 180 mg/dL.
Study NCT03336528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dL and 180 mg/dL.
Study NCT00871546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
Study NCT00871546 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
Study NCT01410292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GI and fiber meals
Description: meals with different fiber content and glycemic index
Study NCT01410292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals
Description: four different meal regarding GI and fiber content
Study NCT01049516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy - Spaced
Description: 10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
Study NCT01049516 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Minimal Contact Control
Description: Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
Study NCT03336528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart
Description: Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
Study NCT04654871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chondroitin Sulfate
Description: Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
Study NCT04654871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval
Study NCT04654871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy / Joint Mobilization
Description: Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
Study NCT04654871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: THE therapy
Description: Interferential and Heating for 20 min
Study NCT04370990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic
Description: O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
Study NCT00866346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1-primed lymphocyte (PR1-CTL) Infusion
Description: Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg.
Study NCT03889236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet Prolon
Description: 5-day fasting mimicking diet
Study NCT03889236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement Endocalyx
Description: Food supplement
Study NCT03889236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00047333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00047333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00047333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03880448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 500mg/8h/7days
Study NCT03336528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart
Description: Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
Study NCT03880448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cornstarch 500mg/8h/7days
Study NCT03880448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal surgery
Description: periodontal surgery
Study NCT03880448 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: periodontal surgery
Description: periodontal surgery
Study NCT00979368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-816336
Description: Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
Study NCT00979368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-816336
Description: Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days